Ona Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ona Therapeutics's estimated annual revenue is currently $5.3M per year.
- Ona Therapeutics's estimated revenue per employee is $142,432
Employee Data
- Ona Therapeutics has 37 Employees.
- Ona Therapeutics grew their employee count by 32% last year.
Ona Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Assistant to CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Medical Officer (Consultant) | Reveal Email/Phone |
4 | BI & BD Manager | Reveal Email/Phone |
5 | PHD Student | Reveal Email/Phone |
6 | Research assistant | Reveal Email/Phone |
Ona Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.4M | 41 | N/A | N/A | N/A |
#2 | $0.9M | 6 | N/A | N/A | N/A |
#3 | $5.9M | 38 | N/A | N/A | N/A |
#4 | $47M | 303 | 18% | N/A | N/A |
#5 | $9.5M | 61 | 11% | N/A | N/A |
#6 | $46.7M | 301 | 25% | N/A | N/A |
#7 | $1.7M | 11 | -8% | N/A | N/A |
#8 | $3.7M | 14 | -30% | N/A | N/A |
#9 | $4.2M | 27 | 23% | N/A | N/A |
#10 | $5.3M | 37 | 32% | N/A | N/A |
What Is Ona Therapeutics?
Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism.
keywords:N/A
N/A
Total Funding
37
Number of Employees
$5.3M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ona Therapeutics News
2022-04-20 - -$0.24 Earnings Per Share Expected for Context Therapeutics ...
Equities research analysts expect Context Therapeutics Inc. ... Its lead product candidate is onapristone extended release (ONA-XR),...
2022-04-06 - Context Therapeutics® Announces Encouraging Preclinical Data from Two
Programs to be Presented at the American Association for Cancer Research
(AACR) Annual Meeting 2022
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models.
Other Companies in Barcelona
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.7M | 37 | 54% | N/A |
#2 | $4.4M | 37 | 54% | N/A |
#3 | $4.5M | 37 | -3% | N/A |
#4 | $6.4M | 38 | -50% | N/A |
#5 | $7.3M | 38 | 23% | N/A |